Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans.
Kanika Vanshylla,Veronica Di Cristanziano,Franziska Kleipass,Felix Dewald,Philipp Schommers,Lutz Gieselmann,Henning Gruell,Maike Schlotz,Meryem S. Ercanoglu,Ricarda Stumpf,Petra Mayer,Matthias Zehner,Eva Heger,Wibke Johannis,Carola Horn,Isabelle Suárez,Norma Jung,Susanne Salomon,Kirsten Alexandra Eberhardt,Kirsten Alexandra Eberhardt,Birgit Gathof,Gerd Fätkenheuer,Nico Pfeifer,Ralf Eggeling,Max Augustin,Clara Lehmann,Florian Klein +26 more
TLDR
In this article, the authors evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19 and found that approximately 3% of individuals demonstrated exceptional SARSCoV2 neutralization, with these "elite neutralizers" also possessing SARS CoV-1 cross-neutralizing IgG.About:
This article is published in Cell Host & Microbe.The article was published on 2021-06-09 and is currently open access. It has received 112 citations till now. The article focuses on the topics: Immunoglobulin G & Neutralizing antibody.read more
Citations
More filters
Journal ArticleDOI
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
TL;DR: In this paper , the authors assessed serum neutralizing capacity in longitudinal cohorts of vaccinated and convalescent individuals, as well as monoclonal antibody activity against Omicron using pseudovirus neutralization assays.
Journal ArticleDOI
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
David Hillus,Tatjana Schwarz,Pinkus Tober-Lau,Kanika Vanshylla,Hana Hastor,Charlotte Thibeault,Stefanie Jentzsch,Elisa T Helbig,Lena J Lippert,Patricia Tscheak,Patricia Tscheak,Marie Luisa Schmidt,Marie Luisa Schmidt,Johanna Riege,Johanna Riege,André Solarek,Christof von Kalle,Chantip Dang-Heine,Henning Gruell,Piotr Kopankiewicz,Norbert Suttorp,Christian Drosten,Christian Drosten,Harald Bias,Joachim Seybold,Florian Klein,Florian Kurth,Florian Kurth,Victor M. Corman,Victor M. Corman,Leif E. Sander +30 more
TL;DR: In this article, an interim analysis of a prospective observational cohort study enrolling health-care workers in Berlin (Germany) who received either homologous ChAdOx1 nCov-19-BNT162b2 vaccination with a 10-12-week vaccine interval was performed.
Journal ArticleDOI
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.
Roanne Keeton,Simone I. Richardson,Simone I. Richardson,Thandeka Moyo-Gwete,Thandeka Moyo-Gwete,Tandile Hermanus,Tandile Hermanus,Marius Belmondo Tincho,Ntombi Benede,Nelia P. Manamela,Nelia P. Manamela,Richard Baguma,Zanele Makhado,Zanele Makhado,Amkele Ngomti,Thopisang Motlou,Thopisang Motlou,Mathilda Mennen,Lionel Chinhoyi,Sango Skelem,Hazel Maboreke,Deelan Doolabh,Arash Iranzadeh,Ashley Otter,Tim Brooks,Mahdad Noursadeghi,James C. Moon,James C. Moon,Alba Grifoni,Daniela Weiskopf,Alessandro Sette,Alessandro Sette,Jonathan M. Blackburn,Nei yuan Hsiao,Carolyn Williamson,Catherine Riou,Ameena Ebrahim Goga,Nigel Garrett,Nigel Garrett,Linda-Gail Bekker,Glenda Gray,Ntobeko A B Ntusi,Penny L. Moore,Penny L. Moore,Wendy A. Burgers +44 more
TL;DR: In this article, the effect of prior infection with different SARS-CoV-2 variants on Ad26.COV2.S immunogenicity was examined, showing that prior infection significantly boosts spike-binding antibodies, antibody-dependent cellular cytotoxicity, and neutralizing antibodies against D614G, Beta, and Delta.
Journal ArticleDOI
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
Liane Dupont,Luke B Snell,Carl Graham,Jeffrey Seow,Blair Merrick,Thomas Lechmere,Thomas J. A. Maguire,Sadie R. Hallett,Suzanne Pickering,Themoula Charalampous,Adela Alcolea-Medina,Isabella Huettner,Jose M. Jimenez-Guardeño,Sam Acors,Nathalia Almeida,Daniel Cox,Ruth E Dickenson,Rui Pedro Galão,Neophytos Kouphou,Marie Jose Lista,Ana Maria Ortega-Prieto,Harry Wilson,Helena Winstone,Cassandra Fairhead,Jia Zhe Su,Gaia Nebbia,Rahul Batra,Stuart J. D. Neil,Manu Shankar-Hari,Jonathan D. Edgeworth,Michael H. Malim,Katie J. Doores +31 more
TL;DR: In this article, the cross-neutralizing activity of SARS-CoV-2 sera was detected up to 305 days post onset of symptoms, although sera were less potent against B.1.7 (Alpha) and B1.617.2 (Delta) variants.
Journal ArticleDOI
Immunity to SARS-CoV-2 induced by infection or vaccination.
TL;DR: In this article, the authors review key findings concerning B cell and antibody responses to SARS-CoV-2, focusing on non-severe cases and anti-spike (S) Ab responses in particular, the latter being central to protective immunity induced by infection or vaccination.
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
A Novel Coronavirus from Patients with Pneumonia in China, 2019.
Na Zhu,Dingyu Zhang,Wenling Wang,Xingwang Li,Bo Yang,Jingdong Song,Xiang Zhao,Baoying Huang,Weifeng Shi,Roujian Lu,Peihua Niu,Faxian Zhan,Xuejun Ma,Dayan Wang,Wenbo Xu,Wenbo Xu,Guizhen Wu,George F. Gao,Wenjie Tan +18 more
TL;DR: Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily, which is the seventh member of the family of coronaviruses that infect humans.
Journal ArticleDOI
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more
TL;DR: Identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China, and it is shown that this virus belongs to the species of SARSr-CoV, indicates that the virus is related to a bat coronav virus.
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
An interactive web-based dashboard to track COVID-19 in real time.
TL;DR: The outbreak of the 2019 novel coronavirus disease (COVID-19) has induced a considerable degree of fear, emotional stress and anxiety among individuals around the world.
Related Papers (5)
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Jennifer M. Dan,Jennifer M. Dan,Jose Mateus,Yu Kato,Kathryn M. Hastie,Esther Dawen Yu,Caterina E. Faliti,Alba Grifoni,Sydney I. Ramirez,Sydney I. Ramirez,Sonya Haupt,April Frazier,Catherine Nakao,Vamseedhar Rayaprolu,Stephen A. Rawlings,Bjoern Peters,Bjoern Peters,Florian Krammer,Viviana Simon,Erica Ollmann Saphire,Erica Ollmann Saphire,Davey M. Smith,Daniela Weiskopf,Alessandro Sette,Alessandro Sette,Shane Crotty,Shane Crotty +26 more
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Pengfei Wang,Manoj S. Nair,Lihong Liu,Sho Iketani,Sho Iketani,Yang Luo,Yicheng Guo,Maple Wang,Jian Yu,Baoshan Zhang,Peter D. Kwong,Peter D. Kwong,Barney S. Graham,John R. Mascola,Jennifer Y Chang,Jennifer Y Chang,Michael T. Yin,Michael T. Yin,Magdalena E. Sobieszczyk,Magdalena E. Sobieszczyk,Christos A. Kyratsous,Lawrence Shapiro,Lawrence Shapiro,Zizhang Sheng,Yaoxing Huang,David D. Ho,David D. Ho +26 more
Evolution of antibody immunity to SARS-CoV-2.
Christian Gaebler,Zijun Wang,Julio C. C. Lorenzi,Frauke Muecksch,Shlomo Finkin,Minami Tokuyama,Alice Cho,Mila Jankovic,Dennis Schaefer-Babajew,Thiago Y. Oliveira,Melissa Cipolla,Charlotte Viant,Christopher O. Barnes,Yaron Bram,Gaëlle Breton,Thomas Hagglof,Pilar Mendoza,Arlene Hurley,Martina Turroja,Kristie Gordon,Katrina G. Millard,Victor A. Ramos,Fabian Schmidt,Yiska Weisblum,Divya Jha,Michael Tankelevich,Gustavo Martinez-Delgado,Jim Yee,Roshni Patel,Juan Dizon,Cecille Unson-O'Brien,Irina Shimeliovich,Davide F. Robbiani,Zhen Zhao,Anna Gazumyan,Robert E. Schwartz,Theodora Hatziioannou,Pamela J. Bjorkman,Saurabh Mehandru,Paul D. Bieniasz,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +43 more